Arch - 24 drugs for clinical trials for Moffitt and DNAP...? I heartily agree with you - that IS good news!
And the nice thing is that DNAP is not depending on the success of any particular drug or trial, but in developing the classifiers during the clinical trials that will in turn help every drug to market...and protect people with safer medication.
BTW, Moffitt won't be doing the trials for us...they will be doing the trials along with us.... They work on the drugs and the effects on their patients...we work on the classifiers to see which patients get good/bad results. I'm pretty sure DNAP is paying some of the costs as well. If they're not...even better!
Great win-win arangement, and with 24 potential clinical trials for DNAP...we win some more...!
Clinical trials for 24 drugs is more than I hoped for (well, I was hoping for an OVANOME update too...lol!).
Bet'cha big pharma is sitting in the corner with eyes wide open...!
God Bless and take care,
Robert
News 
Market Data 
Discover 
AI
